Clinical efficacy and safety of arbekacin sulfate in patients with MRSA sepsis or pneumonia: a multi-institutional study

Totsuka, 1994, Evaluation of once-daily administration of arbekacin. Experimental study and determination of pharmacokinetic properties in man, Jpn J Antibiot, 47, 676 Niijima, 1991, New antimicrobial agent series XL: arbekacin, Jpn J Antibiot, 44, 705 Meiji Seika Pharma Co., Ltd. Package insert of Habekacin® Injection, version 7, 2011. Tanikaze, 2004, Study of clinical significance of PK/PD (pharmacokinetic/pharmacodynamic) parameters after administering arbekacin to patients with pulmonary methicillin-resistant Staphylococcus aureus infection, Jpn J Chemother, 52, 469 Aikawa, 2008, An open clinical study of arbekacin 200 mg q.d. in patients infected with methicillin-resistant Staphylococcus aureus (MRSA)—a clinical pharmacology study, Jpn J Chemother, 56, 299 Begg, 2001, The therapeutic monitoring of antimicrobial agents, Br J Clin Pharmacol, 52, 35S, 10.1046/j.1365-2125.2001.00377.x Sawchuk, 1977, Kinetic model for gentamicin dosing with the use of individual patient parameters, Clin Pharmacol Ther, 21, 362, 10.1002/cpt1977213362 Demczar, 1997, Pharmacokinetics of gentamicin at traditional versus high doses: implications for once-daily aminoglycoside dosing, Antimicrob Agents Chemother, 41, 1115, 10.1128/AAC.41.5.1115 Kobayashi, 2010, Therapeutic drug monitoring survey of anti-MRSA agents in Japan, Jpn J Chemother, 58, 119 Cockcroft, 1976, Prediction of creatinine clearance from serum creatinine, Nephron, 16, 31, 10.1159/000180580 Sato, 2010, Population pharmacokinetic analysis of arbekacin sulfate in adult patients, Jpn J Ther Drug Monit, 27, 98 Kimura, 2011, Dose finding study on arbekacin sulfate for appropriate peak levels, Jpn J Chemother, 59, 597 Ferreira, 2001, Serial evaluation of the SOFA score to predict outcome in critically ill patients, JAMA, 286, 1754, 10.1001/jama.286.14.1754 2008, 4 Kawano, 2010, Postmarketing surveillance review of arbekacin sulfate in patients with therapeutic drug monitoring, Jpn J Ther Drug Monit, 27, 55 Hwang, 2012, The usefulness of arbekacin compared to vancomycin, Eur J Clin Microbiol Infect Dis, 31, 1663, 10.1007/s10096-011-1490-9 Fowler, 2006, Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus, N Engl J Med, 355, 653, 10.1056/NEJMoa053783 Yamamoto, 2012, The efficacy and safety of high-dose arbekacin sulfate therapy (once-daily treatment) in patients with MRSA infection, J Infect Chemother, 18, 241, 10.1007/s10156-012-0397-4